OMER: Omeros Corporation Company Short-Term Debt

omeros.com (OMER) - corporate logo

Omeros Corporation (OMER) business relies on the development of narsoplimab for the therapy of rare thromboses, with the indicator standing at 0.00, while future profits are tied to FDA verdicts. This price chart reflects the company's current market trends. High purification standards and exclusive formula rights create significant barriers to entry for competitors with analogues for years to come.

OMER Omeros Corporation Short-Term Debt (07/04/2022 - 11/01/2026)

Analytical breakdowns and data insights for company Omeros Corp (OMER)

- current quotes and average value forecast:
Price Chart Omeros Corp.|OMER - Fair Value Consensus
- market capitalization information:
Market Value Omeros Corporation|OMER - Total Enterprise Value
- shareholders' equity book value data:
Net Assets per Single Share Omeros|OMER - Total Stockholders' Equity|Market Value to Book Value Ratio omeros.com|OMER - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital Omeros Corporation|OMER - Long-Term Liabilities to Capital|Short-Term Debt to Equity Omeros Corp.|OMER - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Omeros Corporation|OMER - Long-Term Debt|Company Short-Term Debt Omeros|Quick Liquidity Indicator omeros.com
- earnings and multiples data:
OMER - Final Profit
General company analysis:OMER - omeros.com
Manufactured products of Omeros Corp.

Short-term debt represents the total liabilities of a company due for repayment within the next year. This metric measures current liquidity and the business's ability to service operational loans without raising external capital. By analyzing the history of short-term debt changes, an investor assesses the issuer's financial stability. For Omeros Corporation (OMER), low debt levels minimize risks during the development of unique drugs. Stable demand for orphan drugs ensures reliable coverage of these obligations.

Main competitors

BIIB - Company Short-Term Debt|Company Short-Term Loans and Borrowings NBIX (Neurocrine)|Regencell (RGC) - Company Short-Term Debt|Short-Term Debt Axsome Corp (AXSM)|Company Short-Term Debt ACADIA Pharmaceuticals|Short-Term Debt xenon-pharma.com XENE|Company Short-Term Debt Viking Therapeutics, Inc. (VKTX)|Company Current Liabilities Supernus Pharmaceuticals, Inc. SUPN|Company Short-Term Debts CPRX (Catalyst Pharmaceuticals Inc)|Denali Corp (DNLI) - Short-Term Debt|HRMY - Company Short-Term Debt|Company Short-Term Loans and Borrowings BHVN (biohavenpharma.com)|Amylyx Pharmaceuticals, Inc. (AMLX) - Company Short-Term Debt|Short-Term Debt Trevi Therapeutics Inc (TRVI)|Company Short-Term Debt Praxis Medicines|Anavex Life Sciences Corp (AVXL) - Short-Term Debt Volume|Company Current Liabilities CBLL (CeriBell, Inc.)|PRTA (Prothena Corporation plc) - Company Short-Term Loans and Borrowings|Company Short-Term Debts ALEC (Alector)|ANNX - Company Current Liabilities|NGNE - Company Short-Term Debt|Short-Term Debt AC Immune Inc|Voyager Therapeutics (VYGR) - Company Short-Term Debt|neumoratx.com - Company Short-Term Loans and Borrowings|Company Short-Term Debt Scilex|Tevogen Bio Holdings Inc. - Current Liabilities|Company Short-Term Debt Alpha Cognition (ACOG)|CGTX - Short-Term Debt|Company Short-Term Debt Inhibikase Therapeutics IKT|Company Short-Term Loans and Borrowings SAVA|Assertio Therapeutics - Company Short-Term Debts|COYA - Company Short-Term Debts|VTGN (vistagen.com) - Company Current Liabilities|OVID: Amount of Current Liabilities|ABOS (Acumen Pharmaceuticals) - Company Short-Term Debts|cervomed.com (CRVO) - Short-Term Debt Volume|Company Short-Term Debt Alterity Therapeutics (ATHE)|CLNN - Short-Term Debt|Company Short-Term Debt PepGen PEPG|JUNS: Company Short-Term Indebtedness|RLMD - Company Short-Term Debt|Short-Term Debt annovisbio.com|gracetx.com (GRCE) - Company Short-Term Debt|Company Current Liabilities Firefly Neuroscience, Inc.|KLTO (ANEW Medical) - Company Short-Term Debts|Short-Term Debt NeuroSense Therapeutics, Ltd. NRSN|Company Short-Term Debt Reviva Pharmaceuticals (RVPH)|MTVA (metaviatx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NeurAxis NRXS|HSDT: Company Short-Term Indebtedness|Passage Bio Corp - Company Short-Term Debts|Short-Term Debt Neuphoria Therapeutics Inc.|NERV (Minerva Neurosciences) - Company Current Liabilities|athira.com (ATHA) - Company Short-Term Debts|Company Short-Term Debt Addex Therapeutics Ltd|ALZN: Company Short-Term Loans and Borrowings|Company Short-Term Debt Cyclerion Therapeutics (CYCN)|PTIX - Short-Term Debt|Company Short-Term Debt Pasithea Therapeutics Corp. KTTA|Cortigent Inc (CRGT) - Short-Term Debt|ATXI - Company Short-Term Debt|Brainstorm Cell Therapeutics Inc. (BCLI) - Company Current Liabilities|CARA: Company Short-Term Debts|Short-Term Debt Chromocell (CHRO)|Company Short-Term Debt Eliem Therapeutics, Inc.|ITCI: Company Short-Term Loans and Borrowings|Company Short-Term Debt Longboard Pharmaceuticals, Inc. (LBPH)|MRNS - Short-Term Debt|Company Short-Term Debt NKGen NKGN|Short-Term Debt Volume NeuroBo Pharma (NRBO)|SAGE: Company Current Liabilities|Company Short-Term Loans and Borrowings SNPX (synaptogen.com)|TRVN: Company Short-Term Debts|Company Current Liabilities Vigil Neuroscience, Inc.|Company Short-Term Debt Anew Medical, Inc.|Short-Term Debt Cerevel Corp CERE